



Surveillance report 2016 – Sickle cell disease: managing acute painful episodes in hospital (2012) NICE guideline CG143

Surveillance report

Published: 30 August 2016

www.nice.org.uk

Contents

Surveillance decision	3
Reason for the decision.....	3
Commentary on selected new evidence.....	5
How we made the decision	6
New evidence.....	6
Views of topic experts.....	6
Views of stakeholders	6
NICE Surveillance programme project team.....	7

Surveillance decision

We will not update the guideline at this time.

We will transfer the guideline to the [static list](#) because:

- No evidence was identified that would impact on the current guidance and no major ongoing research has been identified as due to be published in the near future (that is, within the next 3–5 years).

Reason for the decision

We found 3 new studies through surveillance of this guideline.

This included new evidence on management of underlying pathology that supports current recommendations. Generally, the topic experts thought that an update was not needed.

We did not find any new evidence on individualised assessment at presentation, primary analgesia, reassessment and ongoing management, possible acute complications, non-pharmacological interventions, setting and training, or discharge information.

None of the new evidence considered in surveillance of this guideline was thought to have an effect on current recommendations.

In addition, no major ongoing studies or research due to be published in the next 3–5 years were identified.

Equalities

One stakeholder has commented that those from socially disadvantaged groups are less likely to speak up about their resultant disadvantages and a 'total care approach' rather than a hospital care approach would reduce this disadvantage. No evidence was identified in relation to this issue from our searches and our recommendations do not exclude these groups.

Overall decision

After considering all the new evidence and views of topic experts, we decided not to update this guideline and to transfer it to the static list.

See [how we made the decision](#) for further information.

Commentary on selected new evidence

With advice from topic experts we did not select any studies for further commentary.

How we made the decision

We check our guidelines regularly to ensure they remain up to date. We based the decision on surveillance 4 years after the publication of [Sickle cell disease: managing acute painful episodes in hospital](#) (2012) NICE guideline CG143.

For details of the process and update decisions that are available, see [ensuring that published guidelines are current and accurate](#) in 'Developing NICE guidelines: the manual'.

Previous surveillance [update decisions](#) for the guideline are on our website.

New evidence

We found 2 new studies in a search for randomised controlled trials and systematic reviews published on 1 January 2014 and 16 February 2016.

Evidence identified in previous surveillance 2 years after publication of the guideline was also considered. This included 1 study identified by search from the 2 year surveillance decision.

From all sources, 3 studies were considered to be relevant to the guideline.

We also checked for relevant ongoing research and none was identified.

See [appendix A](#): summary of new evidence from surveillance and references for all new evidence considered.

Views of topic experts

We considered the views of topic experts, including those who helped to develop the guideline.

Views of stakeholders

Stakeholders commented on the decision not to update the guideline and to transfer the

guideline to the static list. Overall, 2 stakeholders commented. See [appendix B](#) for stakeholders' comments and our responses.

One stakeholder suggested treatment outside the hospital setting should be included, however this is outside the current remit of the guideline and therefore not considered a priority at this time. No comments were received on the proposal to transfer the guideline to the static list therefore this guideline will be transferred to the static list. Both stakeholders disagreed with the decision to remove a research recommendation in relation to the cost effectiveness of daycare units compared to a hospital setting. As it relates to cost effectiveness, it is not expected that this research recommendation would be answered by systematic reviews or randomised controlled trials and a decision was made to retain it. No new ongoing or published studies were identified by the consultees.

See [ensuring that published guidelines are current and accurate](#) in 'Developing NICE guidelines: the manual' for more details on our consultation processes.

NICE Surveillance programme project team

Sarah Willett

Associate Director

Philip Alderson

Consultant Clinical Adviser

Katrina Sparrow

Technical Adviser

Besma Nash

Technical Analyst

The NICE project team would like to thank the topic experts who participated in the surveillance process.

ISBN: 978-1-4731-2045-7